Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Russell P. Rother(Alexion Pharmaceuticals (United States)), Beth E. Petro, Claire Hall(Leeds Teaching Hospitals NHS Trust), Michael P. Bombara(Alexion Pharmaceuticals (France)), Stephen J. Richards(Leeds Teaching Hospitals NHS Trust), Modupe Elebute(St. George Hospital), Judith Marsh(University College Hospital), Scott A. Rollins(Alexion Pharmaceuticals (United States)), Matthew Cullen(Leeds Teaching Hospitals NHS Trust), Christopher F. Mojcik(Alexion Pharmaceuticals (United States))
New England Journal of Medicine
February 4, 2004
10.1056/nejmoa031688
Cited by 637

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k